Navigation Links
Human Genome Sciences to Sponsor Conference Call
Date:3/9/2009

an Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, while the Company has begun shipment of ABthrax to the U.S. Strategic National Stockpile, the Company will continue to face risks related to acceptance of future shipments and FDA's approval of the Company's Biologics License Application for ABthrax, if and when it is submitted. If the Company is unable to meet requirements associated with the ABthrax contract, future revenues from the sale of ABthrax to the U.S. Government will not occur. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
2. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
3. China Biologic Products High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan
4. 14th Annual Wharton Health Care Business Conference to Feature CEOs from WebMD, McKesson, Humana and Given Imaging
5. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
6. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
7. Modigene Awarded Second-Year Grant by Israeli Government to Support Development of Its Longer-Acting Human Growth Hormone
8. Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
9. MultiVu Video Feed: Geron Receives FDA Clearance to Begin Worlds First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
10. Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
11. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/30/2015)... ... 30, 2015 , ... GEA's Pony™ NS2006L is ... up to 1500 bar. The sanitary design gauge of the NS2006L is well ... The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
(Date:7/29/2015)... , July 29, 2015 US-Australian drug ... ) today confirmed it is committed to progressing its ... soon as practicable and to ensure the Company delivers ... Executive Officer, Iain Ross , said the Company ... the lead pre-clinical programs, discovery programs and academic partnerships ...
(Date:7/29/2015)... July 29, 2015  AsureQuality and Ubiquitome have ... for applications in food and primary production sectors. ... real-time PCR device, the Freedom4. AsureQuality ... to the supermarket shelf for producers, processors and ... in animal disease control and pest management and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... appeals to the Senate Judiciary Committee for a hearing regarding covert surveillance ... it were not for the fact that real people are being victimized ... ... Ohio (PRWEB) June 24, 2008 -- As the issue of torturing foreign ...
... -. deCODE genetics,(Nasdaq: DCGN ) today announced that ... R&D event to be held in New York., ... beginning at,1pm Eastern Time/5pm GMT/6pm British Summer time, at ... to last approximately three and a half,hours. The webcast ...
... June 24 ,WuXi PharmaTech (NYSE: WX ) ... announced,that the two companies have entered into a ... which will provide world-class preclinical,contract research services in ... located in a 323,450 square-foot, purpose-built facility in,Suzhou, ...
Cached Biology Technology:Covert Torture, Surveillance Jeopardizes the Freedom of American Citizens 2Covert Torture, Surveillance Jeopardizes the Freedom of American Citizens 3Covert Torture, Surveillance Jeopardizes the Freedom of American Citizens 4deCODE genetics to Webcast Presentations at Annual R&D Event 2deCODE genetics to Webcast Presentations at Annual R&D Event 3Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China 2Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China 3Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China 4
(Date:7/23/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2015.  ... a decrease of 33% compared to $6.8 million in the ... of 2015 was $0.3 million, or $0.01 per diluted share, ... in the same period a year ago.  ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... measly angstrom's difference in diameter is a road-closed sign: ... water-molecule-sized sports car, say scientists at the University of ... a class of proteins that form trans-membrane channels in ... for water movement between the cell and its environment. ...
... management is the key to regulating cell volume says Dutch ... water by the plasma membrane of animal and human cells. ... balance between water uptake and secretion by the cell plasma ... salt concentrations in and around the cell. Exactly how this ...
... Johns Hopkins who has spent nearly three decades studying ... fever warns that the first widespread outbreak of the ... sign of how humans can inadvertently help spread infectious ... to be published in The New England Journal of ...
Cached Biology News:Cells direct membrane traffic by channel width 2Water management in cells 2Infectious disease expert warns of spread of Rocky Mountain spotted fever 2Infectious disease expert warns of spread of Rocky Mountain spotted fever 3
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
Mouse monoclonal antibody raised against a partial recombinant PRKG1. NCBI Entrez Gene ID = PRKG1...
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
Biology Products: